Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyZaltoprofen
Identification
- Name
- Zaltoprofen
- Accession Number
- DB06737
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.
- Structure
Structure for DB06737 (Zaltoprofen)
- Synonyms
- Zaltoprofen
- Zaltoprofene
- Zaltoprofeno
- Zaltoprofenum
- External IDs
- CN 100 / CN-100 / ZC 102
- International/Other Brands
- Borbit (Yoshindo) / Peleton (Towa Yakuhin) / Peon (Zeria Shinyaku) / Salafapinon (Choseido Pharmaceutical) / Soleng (Kyorin Rimedio) / Soleton (CJ Cheiljedang) / Soluirubin (Taiyo Pharmaceutical) / Zaltoprofen Tatsumi Kagaku (Tatsumi Kagaku) / Zatferon (Sawai Seiyaku) / Zyrogen (Yoo Young)
- Categories
- Acids, Acyclic
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Central Nervous System Agents
- Cytochrome P-450 CYP2C9 Substrates
- Fatty Acids
- Fatty Acids, Volatile
- Gout Suppressants
- Lipids
- Peripheral Nervous System Agents
- Pyrans
- Sensory System Agents
- Sulfur Compounds
- UNII
- H8635NG3PY
- CAS number
- 74711-43-6
- Weight
- Average: 298.36
Monoisotopic: 298.066365485 - Chemical Formula
- C17H14O3S
- InChI Key
- MUXFZBHBYYYLTH-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
- IUPAC Name
- 2-{10-oxo-2-thiatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-6-yl}propanoic acid
- SMILES
- CC(C(O)=O)C1=CC=C2SC3=C(C=CC=C3)C(=O)CC2=C1
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when Zaltoprofen is combined with (4R)-limonene. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 5-androstenedione. Experimental, Illicit Abciximab Zaltoprofen may increase the anticoagulant activities of Abciximab. Approved Abiraterone The metabolism of Zaltoprofen can be decreased when combined with Abiraterone. Approved Acebutolol Zaltoprofen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Zaltoprofen. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Zaltoprofen may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zaltoprofen. Approved, Vet Approved Aclarubicin Zaltoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Zaltoprofen. Approved Alclofenac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aldosterone. Experimental, Investigational Aldoxorubicin Zaltoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Alendronic acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid. Approved Aliskiren Zaltoprofen may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alminoprofen. Experimental Alprenolol Zaltoprofen may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Zaltoprofen. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Amcinonide. Approved Amikacin Zaltoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level. Approved, Investigational, Vet Approved Amiloride Zaltoprofen may decrease the antihypertensive activities of Amiloride. Approved Amiodarone The metabolism of Zaltoprofen can be decreased when combined with Amiodarone. Approved, Investigational Amrubicin Zaltoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level. Approved, Investigational Ancrod Zaltoprofen may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Zaltoprofen. Investigational Androstenedione The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anisodamine. Investigational Annamycin Zaltoprofen may decrease the excretion rate of Annamycin which could result in a higher serum level. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Zaltoprofen. Approved, Investigational Antithrombin III human Zaltoprofen may increase the anticoagulant activities of Antithrombin III human. Approved Apalutamide The serum concentration of Zaltoprofen can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban Zaltoprofen may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Apocynin. Investigational Apramycin Zaltoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Zaltoprofen. Approved, Investigational Aprepitant The metabolism of Zaltoprofen can be increased when combined with Aprepitant. Approved, Investigational Arbekacin Zaltoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Zaltoprofen may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Zaltoprofen may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Zaltoprofen may decrease the antihypertensive activities of Arotinolol. Investigational Atamestane The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Atamestane. Investigational Atenolol Zaltoprofen may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Zaltoprofen. Approved Azficel-T The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zaltoprofen. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Zaltoprofen. Investigational Balsalazide Zaltoprofen may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Becaplermin Zaltoprofen may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Beclomethasone dipropionate. Approved, Investigational Befunolol Zaltoprofen may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Zaltoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zaltoprofen. Approved Benorilate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zaltoprofen. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Zaltoprofen. Investigational Betamethasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betamethasone. Approved, Vet Approved Betaxolol Zaltoprofen may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Zaltoprofen. Approved, Investigational Bevantolol Zaltoprofen may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zaltoprofen. Approved, Investigational Bisoprolol Zaltoprofen may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Zaltoprofen may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Zaltoprofen may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Zaltoprofen. Approved Bucillamine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bucillamine. Investigational Bucindolol Zaltoprofen may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Budesonide. Approved Bufexamac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bufexamac. Approved, Experimental Bufuralol Zaltoprofen may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Zaltoprofen. Approved Bupranolol Zaltoprofen may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zaltoprofen. Approved Candoxatril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Candoxatril. Experimental Capecitabine The metabolism of Zaltoprofen can be decreased when combined with Capecitabine. Approved, Investigational Captopril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Captopril. Approved Carbamazepine The metabolism of Zaltoprofen can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zaltoprofen. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Zaltoprofen. Approved, Vet Approved, Withdrawn Carteolol Zaltoprofen may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Zaltoprofen may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Zaltoprofen. Experimental Celecoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Celecoxib. Approved, Investigational Celiprolol Zaltoprofen may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Zaltoprofen can be increased when it is combined with Ceritinib. Approved Certoparin Zaltoprofen may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Zaltoprofen. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen. Approved, Vet Approved Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zaltoprofen. Approved Cholecalciferol The metabolism of Zaltoprofen can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zaltoprofen. Approved Ciclesonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cilazapril. Approved Cinoxacin Zaltoprofen may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Citric Acid Zaltoprofen may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clobetasol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zaltoprofen. Vet Approved Cloranolol Zaltoprofen may decrease the antihypertensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Zaltoprofen can be decreased when combined with Clotrimazole. Approved, Vet Approved Colesevelam Colesevelam can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortisone acetate. Approved, Investigational Crisaborole The metabolism of Zaltoprofen can be decreased when combined with Crisaborole. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zaltoprofen. Experimental Cyclosporine Zaltoprofen may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Zaltoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved Dabrafenib The serum concentration of Zaltoprofen can be decreased when it is combined with Dabrafenib. Approved, Investigational Dalteparin Zaltoprofen may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Zaltoprofen may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Zaltoprofen may increase the anticoagulant activities of Darexaban. Investigational Daunorubicin Zaltoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Approved Deferasirox The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Delapril. Experimental Delavirdine The metabolism of Zaltoprofen can be decreased when combined with Delavirdine. Approved Desirudin Zaltoprofen may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone isonicotinate. Vet Approved Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zaltoprofen. Approved, Investigational Dextran Zaltoprofen may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Zaltoprofen may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Zaltoprofen may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Zaltoprofen may increase the anticoagulant activities of Dextran 75. Approved Dibekacin Zaltoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Zaltoprofen. Approved, Vet Approved Dicoumarol Zaltoprofen may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Zaltoprofen. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Zaltoprofen. Approved Dihydrostreptomycin Zaltoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Zaltoprofen. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zaltoprofen. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zaltoprofen. Approved Dosulepin The metabolism of Zaltoprofen can be decreased when combined with Dosulepin. Approved Doxorubicin Zaltoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Approved, Investigational Drospirenone Zaltoprofen may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Zaltoprofen is combined with E-6201. Investigational Edetic Acid Zaltoprofen may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Zaltoprofen may increase the anticoagulant activities of Edoxaban. Approved Efavirenz The metabolism of Zaltoprofen can be decreased when combined with Efavirenz. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalaprilat. Approved Enoxacin Zaltoprofen may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Zaltoprofen may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Zaltoprofen. Experimental Epanolol Zaltoprofen may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Epirizole. Approved Epirubicin Zaltoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Zaltoprofen. Experimental Eplerenone Zaltoprofen may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zaltoprofen. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen. Approved Equilenin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilin. Approved Esmolol Zaltoprofen may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zaltoprofen. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Zaltoprofen. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ethenzamide. Experimental Ethyl biscoumacetate Zaltoprofen may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etoricoxib. Approved, Investigational Etravirine The metabolism of Zaltoprofen can be decreased when combined with Etravirine. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Evening primrose oil. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Zaltoprofen. Investigational Felbinac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Felbinac. Experimental Fenbufen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Zaltoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Zaltoprofen. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Feprazone. Experimental Ferulic acid Zaltoprofen may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Zaltoprofen. Approved, Investigational Fleroxacin Zaltoprofen may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Zaltoprofen. Approved, Withdrawn Floxuridine The metabolism of Zaltoprofen can be decreased when combined with Floxuridine. Approved Fluasterone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluasterone. Investigational Fluconazole The metabolism of Zaltoprofen can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fludrocortisone. Approved, Investigational Fluindione Zaltoprofen may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Zaltoprofen may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluorometholone. Approved, Investigational Fluorouracil The metabolism of Zaltoprofen can be decreased when combined with Fluorouracil. Approved Fluprednidene The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Zaltoprofen. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zaltoprofen. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone propionate. Approved Fluvastatin The metabolism of Zaltoprofen can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Zaltoprofen can be decreased when combined with Fluvoxamine. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Zaltoprofen. Approved, Nutraceutical, Vet Approved Fondaparinux Zaltoprofen may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Zaltoprofen may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Zaltoprofen. Experimental Formestane The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fosinopril. Approved Fosphenytoin The metabolism of Zaltoprofen can be increased when combined with Fosphenytoin. Approved, Investigational Framycetin Zaltoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Zaltoprofen. Approved, Vet Approved Gabexate Zaltoprofen may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Zaltoprofen may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Zaltoprofen may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Zaltoprofen. Approved, Withdrawn Gemfibrozil The metabolism of Zaltoprofen can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Zaltoprofen may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Zaltoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Zaltoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Zaltoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental GPX-150 Zaltoprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level. Investigational Grepafloxacin Zaltoprofen may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Zaltoprofen is combined with HE3286. Investigational Heparin Zaltoprofen may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Higenamine. Investigational Hydralazine Zaltoprofen may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen. Approved, Vet Approved Hydrocortisone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zaltoprofen. Approved, Investigational Hygromycin B Zaltoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Zaltoprofen. Approved, Investigational Idarubicin Zaltoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level. Approved Idraparinux Zaltoprofen may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen. Approved Indenolol Zaltoprofen may decrease the antihypertensive activities of Indenolol. Withdrawn Indinavir The metabolism of Zaltoprofen can be decreased when combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Zaltoprofen. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Indoprofen. Withdrawn Irbesartan The metabolism of Zaltoprofen can be decreased when combined with Irbesartan. Approved, Investigational Isepamicin Zaltoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Isoxicam. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Istaroxime. Investigational Kanamycin Zaltoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Kebuzone. Experimental Ketoconazole The metabolism of Zaltoprofen can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zaltoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Zaltoprofen. Approved Labetalol Zaltoprofen may decrease the antihypertensive activities of Labetalol. Approved Landiolol Zaltoprofen may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Zaltoprofen. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Zaltoprofen. Approved, Investigational Leflunomide The metabolism of Zaltoprofen can be decreased when combined with Leflunomide. Approved, Investigational Lepirudin Zaltoprofen may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Zaltoprofen may increase the anticoagulant activities of Letaxaban. Investigational Levobunolol Zaltoprofen may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Zaltoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Zaltoprofen. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Zaltoprofen. Approved Lobeglitazone The metabolism of Zaltoprofen can be decreased when combined with Lobeglitazone. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Zaltoprofen. Approved, Investigational Losartan The metabolism of Zaltoprofen can be decreased when combined with Losartan. Approved Loteprednol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loteprednol. Approved Lovastatin The metabolism of Zaltoprofen can be decreased when combined with Lovastatin. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zaltoprofen. Approved, Investigational Lumacaftor The serum concentration of Zaltoprofen can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Zaltoprofen. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zaltoprofen. Approved Manidipine The metabolism of Zaltoprofen can be decreased when combined with Manidipine. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Zaltoprofen. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Zaltoprofen is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zaltoprofen. Approved Melagatran Zaltoprofen may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Zaltoprofen. Approved, Vet Approved Mepindolol Zaltoprofen may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine Zaltoprofen may increase the nephrotoxic activities of Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Zaltoprofen. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zaltoprofen. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Methylprednisolone. Approved, Vet Approved Metipranolol Zaltoprofen may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen. Approved Metoprolol Zaltoprofen may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Metrizamide Zaltoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level. Approved Micronomicin Zaltoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Midostaurin The metabolism of Zaltoprofen can be decreased when combined with Midostaurin. Approved, Investigational Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zaltoprofen. Approved, Experimental Mifepristone The serum concentration of Zaltoprofen can be increased when it is combined with Mifepristone. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Zaltoprofen. Approved Mizoribine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Zaltoprofen. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen. Approved Nabumetone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nabumetone. Approved Nadolol Zaltoprofen may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Zaltoprofen may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Zaltoprofen may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Zaltoprofen. Approved Nalidixic Acid Zaltoprofen may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Zaltoprofen. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Zaltoprofen is combined with NCX 1022. Investigational Neamine Zaltoprofen may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Zaltoprofen may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Zaltoprofen may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin Zaltoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Zaltoprofen. Approved, Investigational Netilmicin Zaltoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The metabolism of Zaltoprofen can be decreased when combined with Nicardipine. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zaltoprofen. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nitroaspirin. Investigational Norfloxacin Zaltoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Zaltoprofen. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen. Approved Olsalazine Zaltoprofen may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Zaltoprofen is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Omapatrilat. Investigational Omeprazole The metabolism of Zaltoprofen can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Orgotein The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Orgotein. Vet Approved Otamixaban Zaltoprofen may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Zaltoprofen. Approved Oxolinic acid Zaltoprofen may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Zaltoprofen may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen. Approved, Withdrawn Pamidronate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parecoxib. Approved Paromomycin Zaltoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Parthenolide. Approved, Investigational Pazufloxacin Zaltoprofen may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Zaltoprofen may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Zaltoprofen may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Zaltoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Zaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Perindopril. Approved Phenindione Zaltoprofen may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenobarbital The metabolism of Zaltoprofen can be increased when combined with Phenobarbital. Approved, Investigational Phenprocoumon Zaltoprofen may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zaltoprofen. Approved, Vet Approved Phenytoin The metabolism of Zaltoprofen can be increased when combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zaltoprofen. Approved, Investigational Pindolol Zaltoprofen may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Zaltoprofen may increase the neuroexcitatory activities of Pipemidic acid. Experimental Pirarubicin Zaltoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level. Investigational Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Zaltoprofen. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen. Approved, Investigational Piromidic acid Zaltoprofen may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Zaltoprofen. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Zaltoprofen may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Zaltoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level. Investigational Plicamycin Zaltoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level. Approved, Investigational, Withdrawn Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Zaltoprofen. Approved Practolol Zaltoprofen may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Zaltoprofen. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisolone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pregnenolone. Approved, Experimental, Investigational Primidone The metabolism of Zaltoprofen can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Zaltoprofen can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propacetamol. Approved, Investigational Propranolol Zaltoprofen may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Zaltoprofen. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Zaltoprofen. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Zaltoprofen. Vet Approved Protein C Zaltoprofen may increase the anticoagulant activities of Protein C. Approved Protein S human Zaltoprofen may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Zaltoprofen may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Zaltoprofen may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Zaltoprofen. Investigational Puromycin Zaltoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Pyrimethamine The metabolism of Zaltoprofen can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quinapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Zaltoprofen. Approved Quinine The metabolism of Zaltoprofen can be decreased when combined with Quinine. Approved Ramipril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen. Approved, Experimental, Investigational Reviparin Zaltoprofen may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Zaltoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rifampicin The metabolism of Zaltoprofen can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Zaltoprofen can be increased when combined with Rifapentine. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate. Approved, Investigational Rivaroxaban Zaltoprofen may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Zaltoprofen may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rucaparib The metabolism of Zaltoprofen can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin Zaltoprofen may increase the neuroexcitatory activities of Rufloxacin. Experimental Sabarubicin Zaltoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Zaltoprofen. Approved Salicylamide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Zaltoprofen. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Zaltoprofen. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Zaltoprofen. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Zaltoprofen. Approved, Investigational Secobarbital The metabolism of Zaltoprofen can be increased when combined with Secobarbital. Approved, Vet Approved Semapimod The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Seratrodast. Approved Serrapeptase The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Serrapeptase. Investigational Sildenafil The metabolism of Zaltoprofen can be decreased when combined with Sildenafil. Approved, Investigational Sisomicin Zaltoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Zaltoprofen may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium phosphate Sodium phosphate may increase the nephrotoxic activities of Zaltoprofen. Approved Sorafenib The metabolism of Zaltoprofen can be decreased when combined with Sorafenib. Approved, Investigational Sotalol Zaltoprofen may decrease the antihypertensive activities of Sotalol. Approved SP1049C Zaltoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level. Investigational Sparfloxacin Zaltoprofen may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spectinomycin Zaltoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level. Approved, Investigational, Vet Approved Spirapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Spirapril. Approved Spironolactone Zaltoprofen may decrease the antihypertensive activities of Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Zaltoprofen. Investigational Streptomycin Zaltoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Streptozocin Zaltoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level. Approved, Investigational Sulfadiazine The metabolism of Zaltoprofen can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Zaltoprofen can be decreased when combined with Sulfamethoxazole. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zaltoprofen. Approved Sulfisoxazole The metabolism of Zaltoprofen can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Zaltoprofen. Approved, Investigational Sulodexide Zaltoprofen may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Zaltoprofen. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Zaltoprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Suxibuzone. Experimental Tacrolimus Zaltoprofen may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Zaltoprofen. Approved Talinolol Zaltoprofen may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Zaltoprofen. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zaltoprofen. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Zaltoprofen. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen. Approved, Investigational Temafloxacin Zaltoprofen may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Zaltoprofen. Approved Tepoxalin The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tepoxalin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Teriflunomide. Approved Tertatolol Zaltoprofen may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zaltoprofen. Approved Ticagrelor The metabolism of Zaltoprofen can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Zaltoprofen can be decreased when combined with Ticlopidine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Zaltoprofen may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tixocortol. Approved, Withdrawn Tobramycin Zaltoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolbutamide The metabolism of Zaltoprofen can be decreased when combined with Tolbutamide. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Zaltoprofen. Approved Topiroxostat The metabolism of Zaltoprofen can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Zaltoprofen. Approved Trandolapril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trandolapril. Approved Tranilast The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tranilast. Approved, Investigational Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Zaltoprofen. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triamcinolone. Approved, Vet Approved Triamterene Zaltoprofen may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zaltoprofen. Approved, Vet Approved Trimethoprim The metabolism of Zaltoprofen can be decreased when combined with Trimethoprim. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triptolide. Investigational Trovafloxacin Zaltoprofen may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Zaltoprofen may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Zaltoprofen. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Valdecoxib. Approved, Investigational, Withdrawn Valproic Acid The metabolism of Zaltoprofen can be decreased when combined with Valproic Acid. Approved, Investigational Valrubicin Zaltoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level. Approved Valsartan The metabolism of Zaltoprofen can be decreased when combined with Valsartan. Approved, Investigational Vancomycin The serum concentration of Vancomycin can be increased when it is combined with Zaltoprofen. Approved Voriconazole The metabolism of Zaltoprofen can be decreased when combined with Voriconazole. Approved, Investigational Warfarin Zaltoprofen may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Zaltoprofen may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zafirlukast The metabolism of Zaltoprofen can be decreased when combined with Zafirlukast. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Zaltoprofen. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen. Withdrawn Zoptarelin doxorubicin Zaltoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. Investigational Zorubicin Zaltoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level. Experimental - Food Interactions
- Not Available
References
- General References
- Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Unknown Status Treatment Injuries, Whiplash 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0139 mg/mL ALOGPS logP 3.55 ALOGPS logP 3.76 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 3.67 ChemAxon pKa (Strongest Basic) -7.6 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 54.37 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 83.69 m3·mol-1 ChemAxon Polarizability 31.16 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dibenzothiepins. These are compounds containing a dibenzothiepin moiety, which consists of two benzene connected by a thiepine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiepins
- Sub Class
- Dibenzothiepins
- Direct Parent
- Dibenzothiepins
- Alternative Parents
- Diarylthioethers / Aryl alkyl ketones / Vinylogous thioesters / Benzenoids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Dibenzothiepin / Diarylthioether / Aryl thioether / Aryl ketone / Aryl alkyl ketone / Benzenoid / Vinylogous thioester / Ketone / Thioether / Monocarboxylic acid or derivatives
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Glucuronosyltransferase activity
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
- Gene Name
- UGT2B7
- Uniprot ID
- P16662
- Uniprot Name
- UDP-glucuronosyltransferase 2B7
- Molecular Weight
- 60694.12 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Drug created on August 31, 2010 14:54 / Updated on March 02, 2018 03:12